On September 1, 2026, AIM-listed Futura Medical (AIM:FUM, OTC:FAMDF) published first-half results that read like two different companies stapled together: a sexual-health pipeline hitting milestone after milestone, and a balance sheet with roughly a month of runway. The maker of Eroxon — the over-the-counter topical gel for erectile dysfunction, the first of its kind cleared for OTC sale in the U.S. and EU — reported revenue of £1.62 million for the six months to June 30, up from £1 million a year earlier, but £1.4 million of that came from a legal settlement with former partner Haleon rather than from selling gel.

Why It Matters

Eroxon is the closest thing the ED category has to a true consumer product — no prescription, no telehealth intake, no pill, just a gel you buy at a counter. That makes Futura a bellwether for whether sexual health can be sold like skincare rather than like medicine. The answer so far is uncomfortable: regulatory clearance and clinical data were never the hard part. Distribution and marketing spend were. Losing Haleon meant losing the retail muscle that gets a first-in-class product onto endcaps, and no amount of positive home-user data substitutes for that. For the broader sector, the story is a caution about partner concentration. A single consumer-health partner can be the entire go-to-market, which means a partnership unwinding is an existential event rather than a setback. Anyone underwriting a sexual-wellness company whose model rests on one big-box or big-pharma relationship should read Futura's half-year as a stress test. There's also a live catalyst worth watching. If FDA clearance for Eroxon Intense lands in Q4 as guided, Futura would hold a strengthened U.S. asset — but on current guidance the cash runs out in October, before that clearance arrives. The next few weeks will determine whether the company reaches its own milestone as an independent business or as somebody else's acquisition. WSD4000, meanwhile, is the quieter prize: a credible topical for female arousal remains one of the least-served segments in sexual health, and Futura is shopping it while it is at its weakest negotiating position.

The headline commercial move is a swap at the top of the U.S. funnel. Effective September 1, Futura appointed Market Performance Group as its new U.S. commercial partner for Eroxon, replacing Haleon after a two-month transition. Haleon — the consumer-health giant spun out of GSK — had been the brand's route into American pharmacy shelves; Market Performance Group is a brand-services and retail-execution firm, a materially different animal. Futura framed it as "a clearer route to rebuilding momentum in one of the world's largest erectile dysfunction markets." The company also said it is in advanced talks with new partners in China, Korea, Taiwan and Turkey, and has consolidated Eroxon manufacturing into a single global supplier.

The pipeline news is genuinely good. Eroxon Intense, a faster- and stronger-acting reformulation, cleared a home user test of 223 men aged 18–59 with what Futura called high efficacy, and has received EU market clearance. The company is targeting FDA clearance for Intense in the fourth quarter, with production expected to begin in early 2027. Separately, WSD4000 — Futura's gel aimed at female sexual arousal, the rarer half of the topical sexual-health market — produced a home user test in which 80% of women reported an improved overall sexual experience. Futura says it has opened early-stage partner discussions for WSD4000 across the U.S., Asia-Pacific, Europe and Latin America.

Then there is the arithmetic. Operating loss narrowed sharply to £1.2 million from £6.72 million (the prior-year figure included £4.05 million of exceptional costs), and administrative expenses fell after cost cuts. But cash stood at £1.06 million as of July 31, down from £1.24 million at the end of June, and the company stated plainly that existing resources fund operations only to approximately October without additional funding. The board says it is "progressing funding initiatives and wider strategic options" — corporate-speak that covers everything from a placing to a sale. Chief executive Alex Duggan characterised the half as "a period of significant strategic progress, strengthening the foundations of the business."

Sources

Update — 2026-09-02

Initial entry — story first created.

Update — 2026-09-24

The "wider strategic options" from the H1 results turned out to mean: the whole company is for sale. On September 3, 2026, Futura Medical issued an RNS titled "Fundraise and launch of FSP and M&A process" — a Rule 2.4 announcement under the City Code on Takeovers and Mergers — confirming it had conditionally raised approximately £1.6 million and formally commenced a Formal Sale Process under Note 2 on Rule 2.6 of the Takeover Code, alongside a parallel M&A process covering potential sales of individual assets and licensing arrangements. This closes the loop on the October cash cliff flagged in the original entry.

The fundraise mechanics. 801,000,000 new ordinary shares at an issue price of 0.2 pence — comprising a firm placing of 58,132,775 shares (~£116,000), a conditional placing of 719,367,225 shares (~£1.43M) and a subscription of 23,500,000 shares (~£47,000) — plus a retail offer via the BookBuild platform for up to £150,000 through up to 75,000,000 further shares. Futura also agreed to issue up to 204,875,000 warrants to Turner Pope Investments, exercisable at the issue price for five years, replacing Turner Pope's cancelled existing warrants. The RNS states completion of the fundraise is expected to extend cash resources into February 2027 — enough runway to actually run a sale process, though the company says additional funding would be required to fully realise the portfolio's commercial potential. Investegate's RNS record shows the retail offer was oversubscribed (RNS, September 8, 2026).

The number that reframes the whole company. Futura's board argues the market valuation does not reflect portfolio value, and singles out WSD4000 — the female sexual arousal gel — as "a highly attractive strategic opportunity." Based on published epidemiology and potential user counts in selected key international markets, the company estimates potential peak annual consumer sales of WSD4000 in excess of US$400 million, against over US$250 million for Eroxon and Eroxon Intense combined. Independently developed, risk-adjusted commercial modelling cited in the RNS indicates potential annual consumer sales of roughly US$445–470 million across key international markets. These are company-commissioned projections, not revenue — but they make explicit what the original entry only implied: the female arousal asset, not the ED franchise, is what Futura believes it is selling.

The downside case is stated in the RNS itself. If the Equity Fundraising Resolutions are not passed, the conditional placing, subscription and retail offer do not proceed. In that scenario, given a cash runway extending only into October 2026, Futura states it is unlikely to be able to carry the M&A or Formal Sale Process to a conclusion — and that the directors would need to consider "an orderly wind-down, solvent or insolvent, or an accelerated insolvent sale." Separately, the company announced on September 10, 2026 that non-executive director Roy Davis will step down effective October 20, 2026, and the RNS feed since early September has filled with Takeover Code Form 8.3 and Form 8 OPD disclosures — the paper trail of a live bid situation.

Why it matters now. A first-in-class, FDA-cleared, drug-free OTC erectile dysfunction treatment and a credible topical for female arousal are being shopped at a 0.2p share price by a company that had five weeks of cash three weeks ago. Whoever buys this is buying regulatory clearance and clinical data at a distressed price — and the strategic logic Futura itself articulates (buyers with "established commercial capabilities, broader distribution networks, complementary product portfolios or operational scale") describes exactly the consumer-health majors the company already failed to retain as a partner.

New Sources

Update — 2026-09-30

The lifeline cleared. At Futura Medical's General Meeting on September 23, 2026, all resolutions in the September 4 circular passed, which removes the "orderly wind-down" scenario described above. Per the company's RNS (as corrected on September 24), all conditions for the placing, subscription and retail offer were met except admission. Application was made to admit 23,500,000 subscription shares, 719,367,225 conditional placing shares and 100,000,000 retail offer shares to AIM, with dealings expected from about September 25. The correction raised the retail figure from the up-to-75,000,000 shares in the original terms, consistent with the oversubscribed BookBuild offer. After admission Futura has 1,482,327,755 ordinary shares in issue. A follow-up PDMR notice confirms the directors themselves took the 23.5 million subscription shares.

The Takeover Code paperwork continues (Rule 2.9 updates, Form 8.3 and Form 8 (DD) disclosures), as expected during a live Formal Sale Process. Read: With the money in and runway into February 2027 per the September 3 RNS, the next catalyst is whether the FSP produces a bidder for Eroxon/WSD4000 or ends in asset-level licensing.

New Sources

Update — 2026-10-07

A stronger Intense dataset as the sale process grinds on. On October 7, 2026, Futura released results from a second home user test (HUT) of Eroxon Intense, which uses an "optimised presentation" meant to make dispensing and application more consistent. The test covered 115 men aged 18–59, most with mild-to-moderate ED, using a design "broadly identical" to the March 23 study so the results can be compared directly. Participants were satisfied with erection hardness in 82% of sexual encounters, compared with 71% for the original Intense presentation and 70% for current Eroxon in the earlier study. Erections lasted long enough for intercourse in 87% of encounters (vs 85% and 84%). IIEF-EF scores improved by 7.86 points from baseline, vs 4.82 for the original Intense. Among men with moderate ED, 87% achieved a clinically meaningful improvement, vs 73% before. The company now targets launch in H1 2027, and R&D head Ken James said "effective positioning and communication around the use of the product will be critical." This is consumer home-use data, not a randomized controlled trial.

The IP and deal backdrop is less encouraging. Around September 30, Futura disclosed that the European Patent Office's Opposition Division had revoked a European patent covering Eroxon (MED3000) following an oral hearing earlier in the year. According to Kalkine Media's summary of the announcement, Futura disagrees, plans to appeal to the Technical Board of Appeal, says the patent stays in force while the appeal runs, and says commercial arrangements, other patents, a pending divisional application and the female WSD4000 programme are unaffected. Takeover Panel disclosures confirm Futura has been in an offer period since September 3 (its Formal Sale Process), and Form 8 filings have continued into October. No bidder has been named.

Read: Futura is pairing better efficacy data with weaker patent protection right in the middle of a sale. A buyer will look at the Intense numbers next to a contested European patent and a cash runway extended only into February 2027. A 7.86-point IIEF gain is respectable for an over-the-counter topical, but in a non-randomized home test it will not settle the questions an acquirer or the FDA will raise.

New Sources

Update — 2026-10-10

The sale timetable slips and the finance chief heads for the exit. On October 8, 2026, Futura said the board now expects to invite non-binding offers "over the next four weeks", replacing the original October 2 deadline. It reported "strong interest" since the Formal Sale Process began on September 3 and said information memoranda have gone out to prospective bidders. As usual, it added that there is no certainty of an offer or a deal. Finance director and COO Angela Hildreth steps down from her executive roles on November 13, 2026 but stays on the board as a non-executive director for the rest of the M&A and sale process. Maddy Kennedy starts as interim CFO on October 12 on a consultancy basis, and company-secretarial work moves to the outsourced provider ESGovernance.

Read: A delayed bid date usually means one of two things. Either bidders want more diligence time, which here probably means time with the contested European patent and the new Eroxon Intense data from October 7, or the board is trying to get a competitive tension that hasn't formed yet. Losing the executive who knows the numbers best in the middle of a sale is a yellow flag. Keeping her on the board softens it. The decision point to watch is now early November, which overlaps with Hildreth's exit date and the targeted Q4 FDA clearance for Eroxon Intense.

New Sources